# Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

> **NCT00243659** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 30 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** ReFacto AF

## Key facts

- **NCT ID:** NCT00243659
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2011-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243659, "Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00243659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*